论文部分内容阅读
目的:观察内镜下前房角分离联合超声乳化人工晶状体植入术治疗原发性闭角型青光眼伴发白内障的临床效果。方法:采用前瞻性病例研究。对无锡市第二人民医院眼科2018年11月至2019年4月原发性闭角型青光眼伴发白内障33例(33只眼)，采用内镜下前房角分离联合超声乳化人工晶状体植入术。术后随访6 ～ 10个月。观察术后视力、眼压、抗青光眼药物种类、前房角开放范围及并发症的发生率。结果:末次随访时眼压(15.01±4.37)mmHg(1 mmHg＝0.133 kPa)，较术前(28.58±11.14)mmHg明显下降(n t＝8.353，n P<0.001)。术后最佳矫正视力(logMAR)0.64±0.32较术前的1.02±0.36提高(n t＝1.382，n P＝0.074)；术前使用抗青光眼药物数量(3.48±0.94)种降至(0.24±0.66)种，差异具有统计学意义(n t＝6.372，n P＝0.008)；术后前房角开放范围达270°者28只眼(84.85%)，相比术前差异具有统计学意义(n χ2＝91.495，n P<0.001)。随访期间未见明显并发症。n 结论:内镜下前房角分离联合超声乳化人工晶状体植入术治疗闭角型青光眼伴白内障安全有效。“,”Objective:To observe the clinical efficacy of endoscopic goniosynechialysis combined with phacoemulsification and intraocular lens implantation in primary angle-closure glaucoma with cataract.Methods:This was a prospective case study. A total of 33 eyes of 33 patients with primary angle-closure glaucoma combined with cataract from Nov. 2018 to Apr. 2019 in Wuxi No.2 People’s Hospital were enrolled. All patients underwent endoscopic goniosynechialysis combined with phacoemulsification and intraocular lens implantation. All patients were followed up for 6 to 10 months. Postoperative visual acuity, IOP, the kinds of anti-glacucoma drugs, the opening range of anterior chamber angle and complications were obseroved.Results:At the last follow-up, the IOP was (15.01±4.37) mmHg (1 mmHg=0.133 kPa), which decreased significantly from (28.58±11.14) mmHg before operation (n t=8.353, n P<0.001). The best corrected visual acuity (logMAR) was 0.64±0.32 after operation, which was better than the 1.02±0.36 before operation(n t=1.382, n P=0, 074). The kinds of anti-glaucoma medications decreased from 3.48±0.94 to 0.24±0.66, and the difference was statistically significant(n t=6.372, n P=0.008). The opening range of anterior chamber angle reached 270°in 28 eyes (84.85%), and the difference was statistically significant before and after operation (n χ2=91.495, n P<0.001). No obvious complication occurred.n Conclusion:Endoscopic goniosynechialysis combined with phacoemulsification and intraocular lens implantation is safe and effective for primary angle-closure glaucoma with cataract.